EXPAREL
Total Payments
$48.4M
Transactions
38,492
Doctors
17,236
Companies
6
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.1M | 16 | 2 |
| 2023 | $167,821 | 5 | 1 |
| 2022 | $10,248 | 10 | 7 |
| 2021 | $17,498 | 22 | 15 |
| 2020 | $9.0M | 4,242 | 2,520 |
| 2019 | $12.1M | 11,855 | 6,772 |
| 2018 | $9.6M | 10,407 | 5,306 |
| 2017 | $16.4M | 11,935 | 5,550 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $27.6M | 1,370 | 57.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6.4M | 2,332 | 13.2% |
| Current or prospective ownership or investment interest | $5.5M | 131 | 11.3% |
| Consulting Fee | $3.7M | 1,449 | 7.6% |
| Travel and Lodging | $1.7M | 5,900 | 3.6% |
| Food and Beverage | $1.3M | 26,832 | 2.7% |
| Grant | $1.3M | 49 | 2.7% |
| Space rental or facility fees (teaching hospital only) | $396,617 | 55 | 0.8% |
| Gift | $270,969 | 19 | 0.6% |
| Education | $181,253 | 354 | 0.4% |
| Charitable Contribution | $890.00 | 1 | 0.0% |
Payments by Type
Research
$27.6M
1,370 transactions
General
$20.8M
37,122 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF FEMORAL NERVE BLOCK WITH EXPAREL FOR POSTSURGICAL ANALGESIA IN SUBJECTS UNDERGOING TOTAL KNEE ARTHROPLASTY | Pacira Pharmaceuticals Incorporated | $3.3M | 0 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BRACHIAL PLEXUS BLOCK WITH EXPAREL FOR POSTSURGICAL ANALGESIA IN SUBJECTS UNDERGOING TOTAL SHOULDER ARTHROPLASTY OR ROTATOR CUFF REPAIR | Pacira Pharmaceuticals Incorporated | $2.7M | 0 |
| A MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EXPAREL WHEN ADMINISTERED VIA INFILTRATION INTO THE TRANSVERSUS ABDOMINIS PLANE VERSUS STANDARD OF CARE IN SUBJECTS UNDERGOING ELECTIVE CESAREAN SECTION | Pacira Pharmaceuticals Incorporated | $2.2M | 0 |
| COMPARISON OF BILATERAL TRANSVERSUS ABDOMINIS PLANE BLOCK WITH EXPAREL VERSUS CONTINUOUS EPIDURAL ANALGESIA WITH BUPIVACAINE A RANDOMIZED, CONTROLLED TRIAL | Pacira Pharmaceuticals Incorporated | $1.8M | 0 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EXPAREL WHEN ADMINISTERED VIA INFILTRATION INTO THE TRANSVERSUS ABDOMINIS PLANE TAP VERSUS BUPIVACAINE ALONE IN SUBJECTS UNDERGOING ELECTIVECESAREANSECTION | Pacira Pharmaceuticals Incorporated | $1.5M | 0 |
| A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THREE-PERIOD, THREE-SEQUENCE CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF TWO LOTS OF EXPAREL FROM DIFFERENT MANUFACTURING FACILITIES FOLLOWING ADMINISTRATION VIA LOCAL INFILTRATION TO HEALTHY SUBJECTS | Pacira Pharmaceuticals Incorporated | $1.4M | 0 |
| A PHASE 1, PILOT, OPEN LABEL, DOSE ESCALATION STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY, OF EXPAREL ADMINISTERED AS SCIATIC NERVE BLOCK IN POPLITEAL FOSSA, FOR POSTSURGICAL ANALGESIA IN SUBJECTS UNDERGOING BUNIONECTOMY | Pacira Pharmaceuticals Incorporated | $1.2M | 0 |
| A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED TRIAL COMPARING LOCAL INFILTRATION ANALGESIA WITH EXPAREL TO LOCAL INFILTRATION ANALGESIA WITHOUT EXPAREL TO MANAGE POSTSURGICAL PAIN FOLLOWING TOTAL KNEE ARTHROPLASTY | Pacira Pharmaceuticals Incorporated | $1.0M | 1 |
| A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. | Pacira Pharmaceuticals Incorporated | $964,635 | 0 |
| A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS (PLAY) | Pacira Pharmaceuticals Incorporated | $942,681 | 0 |
| A PHASE 1, PILOT, OPEN LABEL, STUDY TO EVALUATE THE PHARMACOKINETICS, AND SAFETY, OF EXPAREL ADMINISTERED AS PECTORAL PLANE BLOCK IN WOMEN UNDERGOING BREAST AUGMENTATION SURGERY | Pacira Pharmaceuticals Incorporated | $926,288 | 0 |
| A PHASE 1, RANDOMIZED, DOUBLE BLIND, THREE PERIOD, THREE SEQUENCE CROSSOVER STUDY WITH AN OPTIONAL OPEN-LABEL FOURTH PERIOD TO EVALUATE THE BIOEQUIVALENCE OF UP TO THREE LOTS OF EXPAREL FOLLOWING ADMINISTRATION VIA LOCAL INFILTRATION TO HEALTHY SUBJECTS | Pacira Pharmaceuticals Incorporated | $901,186 | 0 |
| Mylan BUPI-ISL-1003 | Mylan Pharmaceuticals Inc. | $730,764 | 0 |
| A MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A SINGLE-DOSE OF EXPAREL VS. USUAL CARE FOR POSTSURGICAL ANALGESIA AFTER POSTERIOR LUMBAR SPINE FUSION SURGERY | Pacira Pharmaceuticals Incorporated | $728,439 | 0 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF EXPAREL FOR POSTSURGICAL PAIN MANAGEMENT IN SUBJECTS UNDERGOING OPEN LUMBAR SPINAL FUSION SURGERY | Pacira Pharmaceuticals Incorporated | $705,199 | 0 |
| CHARACTERIZATION OF BIO-PSYCHOSOCIAL PAIN PROFILES IN THE PERIOPERATIVE PERIOD | Pacira Pharmaceuticals Incorporated | $571,814 | 0 |
| PHASE 1, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO CONTROLLED, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF EXPAREL? ADMINISTERED VIA A SINGLE INTRATHECAL INJECTION TO HEALTHY VOLUNTEERS | Pacira Pharmaceuticals Incorporated | $557,443 | 0 |
| Mylan-BUPI-ISL-1001 | Mylan Pharmaceuticals Inc. | $522,570 | 0 |
| RETROSPECTIVE ANALYSIS OF PEDIATRIC UTILIZATION OF LOPOSOMAL BUPIVACAINE | Pacira Pharmaceuticals Incorporated | $468,605 | 0 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BRACHIAL PLEXUS BLOCK WITHEXPAREL FOR POSTSURGICAL ANALGESIA INSUBJECTSUNDERGOING TOTALSHOULDERARTHROPLASTY OR ROTATOR CUFF REPAIR | Pacira Pharmaceuticals Incorporated | $325,760 | 0 |
Top Doctors Receiving Payments for EXPAREL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| James Hinson | — | Nashville, TN | $29.4M | 1,558 |
| Nicholas Robinson | — | Buffalo, NY | $2.4M | 2 |
| , M.D | Anesthesiology | Brooklyn, NY | $1.2M | 120 |
| , MD | Orthopaedic Surgery | Cleveland, OH | $1.1M | 144 |
| , M.D | Anesthesiology | Houston, TX | $621,600 | 60 |
| , M.D | Anesthesiology | Cleveland, OH | $429,497 | 598 |
| , M.D | Anesthesiology | Minneapolis, MN | $420,040 | 592 |
| , MD | Anesthesiology | Durham, NC | $415,260 | 472 |
| , MD | Anesthesiology | Aurora, CO | $406,840 | 298 |
| , M.D | Anesthesiology | Cleveland, OH | $351,474 | 550 |
| , M.D | Pediatric Anesthesiology | Marietta, GA | $342,142 | 548 |
| , M.D | Anesthesiology | Dallas, TX | $313,246 | 472 |
| Darin Rentz | Anesthesiology | Lakewood, CO | $311,199 | 27 |
| , M.D | Orthopaedic Surgery | Loma Linda, CA | $305,893 | 347 |
| Valentine Gibson | Anesthesiology | Dallas, TX | $228,265 | 381 |
| , MD | Adult Reconstructive Orthopaedic Surgery | Fremont, CA | $226,820 | 110 |
| , D.O | Anesthesiology | Minneapolis, MN | $216,393 | 347 |
| Tracey Henry | Internal Medicine | Atlanta, GA | $208,210 | 2 |
| Stanley Dysart | — | Marietta, GA | $183,289 | 219 |
| , MD | Obstetrics & Gynecology | Celebration, FL | $178,846 | 239 |
| , MD | Anesthesiology | Hartford, CT | $175,298 | 180 |
| , M.D | Orthopaedic Surgery | Greenwich, CT | $174,911 | 143 |
| , M.D | Orthopaedic Surgery | Kenner, LA | $160,425 | 42 |
| , MD | Student in an Organized Health Care Education/Training Program | Fort Worth, TX | $157,717 | 270 |
| Stuart Lieblich | — | Avon, CT | $150,933 | 148 |
Ad
Manufacturing Companies
- Pacira Pharmaceuticals Incorporated $46.1M
- Mylan Pharmaceuticals Inc. $1.3M
- Medical Device Business Services, Inc. $1.0M
- DePuy Synthes Sales Inc. $26,367
- DePuy Synthes Products, Inc. $1,560
- Ethicon US, LLC $1,288
Product Information
- Type Drug
- Total Payments $48.4M
- Total Doctors 17,236
- Transactions 38,492
About EXPAREL
EXPAREL is a drug associated with $48.4M in payments to 17,236 healthcare providers, recorded across 38,492 transactions in the CMS Open Payments database. The primary manufacturer is Pacira Pharmaceuticals Incorporated.
Payment data is available from 2017 to 2024. In 2024, $1.1M was paid across 16 transactions to 2 doctors.
The most common payment nature for EXPAREL is "Unspecified" ($27.6M, 57.0% of total).
EXPAREL is associated with 20 research studies, including "A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF FEMORAL NERVE BLOCK WITH EXPAREL FOR POSTSURGICAL ANALGESIA IN SUBJECTS UNDERGOING TOTAL KNEE ARTHROPLASTY" ($3.3M).